ASSET PURCHASE AGREEMENT by and between MARO BIO INC., a Delaware corporation and GRAPHITE BIO, INC., a Delaware corporation Dated as of August 1, 2023Asset Purchase Agreement • February 5th, 2024 • Graphite Bio, Inc. • Biological products, (no disgnostic substances) • Delaware
LICENSE AND OPTION AGREEMENTLicense and Option Agreement • February 5th, 2024 • Graphite Bio, Inc. • Biological products, (no disgnostic substances) • California
This License and Option Agreement (this “Agreement”) is entered into as of August 4, 2023 (the “Effective Date”), by and between Kamau Therapeutics, Inc., a corporation existing under the laws of Delaware, having a place of business at [***] (“Licensee”) and Graphite Bio, Inc. a corporation existing under the laws of Delaware, having a place of business at 201 Haskins Way, Suite 210, South San Francisco, CA 94080 (“Graphite”). Each of Licensee and Graphite is referenced herein as a “Party” and collectively, the “Parties.”
